Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
salutaxel
- Development stage
- Phase 1
- Lead developer
- Ningbo Combireg Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Salutaxel (CP-0127) is a novel, next-generation taxane derivative developed by Ningbo Comprege Pharmaceutical Technology Co., Ltd. for the treatment of advanced solid tumors. Like other taxanes, it functions as a microtubule stabilizer by binding to the beta-subunit of tubulin, promoting microtubule assembly and inhibiting depolymerization. This stabilization disrupts the dynamic equilibrium of the microtubule network, leading to cell cycle arrest at the G2/M phase and subsequent apoptosis. Salutaxel is engineered to potentially offer improved efficacy and a better safety profile compared to first-generation taxanes, particularly in patients with taxane-resistant tumors. It is currently undergoing Phase 1/2 clinical evaluation in China for various solid tumor indications.
- Other names
- salutaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on salutaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on salutaxel.